Company News 27 Jun 2025 First US Surgical Use of Remplir™ Orthocell recorded first use of Remplirâ„¢ in the US overnight, which is an important step in establishing surgical experience and… Orthocell
Company News Back view of young disabled black man in wheelchair spreading his arms, feeling happy and free on walk at city park. Full length of handicapped guy with backpack going on trip outdoors 19 Jun 2025 Breakthrough Study Confirms Remplirâ„¢ Superiority Over Standard US Nerve Repair Technique Orthocell has today announced interim results from a new study demonstrating that Remplirâ„¢ delivers superior nerve regeneration, earlier return to… Orthocell
Company News 12 May 2025 Orthocell Receives Regulatory Approval for Remplirâ„¢ in Hong Kong Orthocell has received regulatory approval from the Hong Kong Department of Health's Medical Device Division to commence sales of Remplirâ„¢… Orthocell
Company News 09 May 2025 Orthocell US Remplirâ„¢ Sales Rollout Gains Pace with 12 Distributors Now Appointed Covering 21 States Orthocell has appointed 12 US distributors for its nerve repair product Remplirâ„¢, well ahead of the expected target of 10… Orthocell
Company News 30 Apr 2025 Orthocell Secures Health Canada Approval for Remplirâ„¢ in US$75 million Canadian Market Orthocell has secured a Medical Device Licence from Health Canada for Remplirâ„¢, opening access to the US$75 million Canadian nerve… Orthocell
Company News 28 Apr 2025 Orthocell Receives Regulatory Approval to Commence Sales of Remplirâ„¢ in US$84 million Thai market Orthocell has been granted a licence by the Food and Drug Administration of Thailand to commence sales of Remplirâ„¢ into… Orthocell
Company News 24 Apr 2025 Orthocell Appoints its First Four US Remplirâ„¢ Distributors Orthocell has appointed four US distributors for its flagship nerve repair product Remplirâ„¢, enabling the commencement of commercial distribution into… Orthocell
Company News 09 Apr 2025 Orthocell Receives Regulatory Approval for Striate+ in Brazil Orthocell has announced that Brazilian Health Regulatory Agency, ANVISA, has granted regulatory approval for the Company’s market-leading dental membrane, Striate+â„¢,… Orthocell
Company News 04 Apr 2025 US FDA grants 510(k) clearance for Orthocell’s flagship Remplirâ„¢ nerve repair product Orthocell has announced that the US Food and Drug Administration has granted regulatory clearance under the 510(k) pathway for the… Orthocell
Company News 26 Mar 2025 First Sales of Striate+â„¢ in DACH Region Orthocell has today announced that our exclusive global distribution partner BioHorizons has officially completed first sales of Orthocell’s dental product,… Orthocell
